Multiple Dosing Options


PULMICORT RESPULES is a branded inhaled corticosteroid (ICS) with a once-daily dosing option approved for patients 12 months to 8 years of age.1,2 PULMICORT RESPULES is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm.2

With a once-daily dosing option, PULMICORT RESPULES can be administered once or twice daily, in varying doses, to help meet your patients’ needs. Once-daily and twice-daily dosing options also allow for therapy adjustments.2 PULMICORT RESPULES 1 mg should not be used more than once per day.2

PULMICORT RESPULES was effective dosed once or twice daily. However, when all measures are considered together, the evidence is stronger for twice-daily dosing.2


Each patient's starting dose is based on previous therapy, rather than on body weight.2



Recommended starting doses2

PULMICORT RESPULES® (budesonide inhalation suspension) dosing

Additional dosing considerations

  • In symptomatic patients not responding to nonsteroid asthma therapy, a starting dose of 0.25 mg once daily of PULMICORT RESPULES may be considered2
  • If once-daily treatment does not provide adequate control, the total daily dose should be increased and/or administered as a divided dose
  • Improvement in asthma control can occur within 2 to 8 days of initiation of treatment, although maximum benefit may not be achieved for 4 to 6 weeks2
  • Once the desired clinical effect is achieved, consideration should be given to titrating to the lowest effective dose2
  • Particular care is needed for patients who are transferred from systemically active corticosteroids to less systemically available corticosteroids, because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids (see WARNINGS in full Prescribing Information )2

IMPORTANT SAFETY INFORMATION ABOUT PULMICORT RESPULES


PULMICORT RESPULES is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm.

Particular care is needed for patients who are transferred from systemically active corticosteroids to PULMICORT RESPULES, because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids.

It is possible that systemic corticosteroid effects such as hypercorticism, reduced bone mineral density, and adrenal suppression may appear in a small number of patients, particularly at higher doses.

Patients taking immunosuppressant doses of corticosteroids should avoid exposure to infections such as chicken pox and measles.

Inhaled corticosteroids may cause a reduction in growth velocity. The long-term effect on final adult height is unknown.

Hypersensitivity reactions, including anaphylaxis, have been reported with budesonide.

As with other inhaled medications, paradoxical bronchospasm may occur with
PULMICORT RESPULES.

In rare cases, patients on inhaled corticosteroids may present with systemic eosinophilic conditions and clinical features consistent with Churg-Strauss Syndrome.

Adverse reactions that occurred at a rate of ≥ 3% are: respiratory infection, rhinitis, coughing, otitis media, viral infection, moniliasis, gastroenteritis, vomiting, diarrhea, abdominal pain, ear infection, epistaxis, conjunctivitis, and rash.


Indication


PULMICORT RESPULES (budesonide inhalation suspension) is indicated for the maintenance treatment of asthma and as prophylactic therapy in children ages 12 months to 8 years.

Please click here for full Prescribing Information for PULMICORT RESPULES.  

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

PULMICORT RESPULES® (budesonide inhalation suspension) – Pediatric Asthma Treatment

Help educate parents on jet nebulizers and how they work in children by delivering medication directly to the lungs.

Get started now